查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2126358

伴隨診斷軟體市場：策略性洞察與預測（2026-2035 年）

Companion Diagnostics Software Market - Strategic Insights and Forecasts (2026-2035)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 173 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計伴隨診斷軟體市場將從 2026 年的 11.2 億美元成長到 2035 年的 40.4 億美元，複合年成長率為 15.3%。

伴隨診斷軟體市場正經歷顯著的變革，其驅動力來自精準醫療的模式轉移以及基因組數據解讀日益成長的複雜性。這個市場演變的特點是，人們越來越認知到軟體平台在將基因組和分子資訊轉化為臨床應用見解以及實現精準的患者分層以進行標靶治療發揮著至關重要的作用。次世代定序、人工智慧和雲端運算的融合，使得資料解讀更有效率、擴充性且具有臨床意義。隨著檢測數量的增加，人工分析方法已難以為繼，促使醫療系統和製藥公司採用數位化精準醫療工作流程。此外，隨著軟體分析結果對治療選擇和患者預後的影響日益增強，監管力道也不斷增加。透過對人工智慧驅動的分析平台、雲端生態系統和互通軟體環境的大量投資，伴隨診斷軟體已成為實現精準醫療的關鍵基礎，其作用貫穿從診斷檢測到治療決策的整個過程。

市場促進因素

  • 精準醫療專案的擴展是伴隨診斷軟體市場的主要驅動力。精準醫療需要準確的分子層次解讀來支持治療方案的選擇。隨著製藥公司研發管線中生物標記標靶療法的日益增多，對精準醫療的需求也不斷成長。檢測量的增加加重了工作流程的負擔，因為檢查室必須在保證準確性的前提下快速處理基因組資訊。軟體開發商正在擴展自動化分析功能以提高效率。這一趨勢正在增強對伴隨診斷軟體解決方案的長期需求，並推動伴隨診斷軟體使用量的持續成長。由於資料複雜性的增加，次世代定序(NGS) 的日益普及進一步加速了市場擴張。 NGS 產生全面的分子資料集，為個人化醫療決策提供支援。隨著臨床醫生需要在多個疾病領域進行更廣泛的基因組分析，NGS 的應用也不斷增加。資料的複雜性帶來了解讀方面的挑戰，因為傳統的分析方法難以處理大規模的定序結果。軟體供應商正在開發先進的分析功能和自動化報告系統來滿足這些需求。這種發展進一步提升了軟體在整個診斷工作流程中的重要性。監管機構對診斷準確性的日益重視正在推動檢驗軟體平台的普及。監管機構強調精準醫療應用中的分析有效性和臨床效用。隨著伴隨診斷對治療結果的影響日益增強，監管力道也不斷加強。合規要求給檢查室帶來了營運負擔，要求其記錄調查方法和報告的一致性。供應商正在加強品管和審計能力以滿足監管要求。這些趨勢正在推動企業級軟體平台的普及。臨床數據和基因組數據的整合正在促進精準醫療在醫療保健領域的應用。如今，臨床決策依賴將分子層面的觀察與患者個別資訊結合。僅憑基因組數據只能提供有限的治療背景信息，因此對高級數據的需求不斷成長。分散的醫療保健數據環境通常導致資訊散落在不同的系統中，阻礙了全面分析。軟體供應商正在開發可互通的平台，以連接檢查室和臨床資料庫。

市場限制因素

  • 實施和整合先進軟體的高成本（通常需要大量的基礎建設投資）限制了小規模醫療機構的採用。這種沉重的經濟負擔對小規模機構來說是一個障礙。基因組資訊是高度敏感的患者數據，這增加了數據隱私和網路安全的操作複雜性。基因組數據的高度敏感度也帶來了額外的管理要求。標準化基因組解讀框架的匱乏限制了管治，可能導致不同機構採用不同的變異分類方法。缺乏統一標準給一致的解讀帶來了挑戰。與現有檢查室和醫療系統的整合挑戰可能導致實施延遲和操作摩擦。

對技術和軟體類型的深入了解

  • 軟體發展趨勢的特徵是整合精準醫療平台的重要性日益凸顯，這些平台融合了資料解讀、工作流程管理和臨床決策支援功能。基因組數據解讀軟體至關重要，因為伴隨診斷越來越依賴精準的分子表徵。隨著新一代定序（NGS）產生的大規模資料集超出人工解讀的能力，對解讀軟體的需求也不斷成長。隨著變異複雜性的增加，檢查室面臨更大的分析負擔，因為他們必須區分具有臨床意義的觀察和背景基因組變異。軟體開發人員正致力於透過增強資料庫、自動化註釋工具和實證報告框架來提高解讀效率。臨床決策支援軟體將基因組分析結果轉化為具體的治療建議。實驗室資訊管理軟體有助於最佳化工作流程和進行資料管理。生物資訊分析軟體支援高級基因組數據處理。細分市場分析表明，隨著醫療機構需要靈活的資源來處理日益成長的分子檢測量，基於雲端的採用正在擴大。基因組資料集規模和複雜性的不斷成長，對資料儲存提出了更高的要求，這給營運帶來了挑戰。隨著標靶治療越來越依賴基於生物標記的治療選擇，腫瘤學仍然是一個重要的應用領域。隨著製藥公司在多種腫瘤類型中拓展精準腫瘤學產品線，市場需求不斷成長。製藥和生物技術公司是主要的終端用戶群體，診斷檢查室和醫療機構的應用也日益廣泛。人工智慧的整合變得越來越重要，因為它能夠識別具有臨床意義的基因組模式，從而改善診斷解讀。供應商正在將機器學習演算法融入解讀工作流程，以提高效率。

競爭環境與策略展望

  • 在競爭激烈的市場格局中，除了專業的基因組分析公司外，成熟的診斷、生命科學和醫療保健技術供應商也紛紛湧入市場。 SOPHiA GENETICS 透過將雲端原生分析、人工智慧和基因組解讀功能整合到一個統一的精準醫療平台中，並擴展 SOPHiA DDM 平台以提升自動化突變分類和臨床決策支援能力，從而保持了獨特的戰略地位。羅氏診斷 (Roche Diagnostics) 憑藉其在藥物開發、伴隨診斷和數位健康能力整合方面的優勢，正在增強其軟體驅動的基因組解讀能力，以滿足精準醫療不斷變化的需求。凱傑 (QIAGEN) 憑藉其強大的分子診斷產品組合和生物資訊基礎設施脫穎而出，並正在加強其數位解讀平台和資料庫，以滿足日益成長的基因組檢測需求。隨著定序技術的普及不斷推動對基因組分析軟體的需求，Illumina 佔據了戰略地位，並正在擴展其軟體驅動的分析能力，以支持數據分析和報告。賽默飛世爾科技正利用其廣泛的生命科學和分子診斷產品組合，支持伴隨診斷工作流程，並擴展其數位生物資訊能力，以推動精準醫療的普及。安捷倫憑藉其在分子分析、病理工作流程和伴隨診斷支援技術方面的專業知識脫穎而出，並不斷強化其軟體解決方案，以最佳化檢查室工作流程並支援分子分析。Oracle健康正利用其豐富的醫療資訊技術專業知識和數據整合能力，擴展其醫療分析和雲端基礎設施能力，以支援基因組和臨床數據的整合。西門子健康保險透過結合診斷技術、醫療資訊學和數位健康解決方案，保持競爭優勢，並擴展其數位健康能力，以支援先進的診斷和決策流程。每家公司都在透過在人工智慧驅動的解讀、雲端平台和互通軟體環境方面的創新來推動產品系列的擴展。在支持整合生物標記開發的需求推動下，軟體供應商和製藥公司之間的策略合作夥伴關係正在增加。近期重要進展包括Indica Labs宣布大幅擴展其伴隨診斷能力，使其在精準醫療創新領域中領先地位。 Labcorp宣布Agilent Technologies的PD-L1 IHC 22C3 pharmDx在全美範圍內上市，這是目前唯一獲得FDA批准的伴隨診斷試劑，用於識別可能適合使用默克公司KEYTRUDA的含鉑類藥物抗藥性卵巢癌患者。地理擴張仍然是關鍵策略重點，各公司正將目光投向快速成長的亞太地區以及醫療基礎設施不斷完善的新興市場。

簡明結論

  • 伴隨診斷軟體市場預計將持續成長，這主要得益於精準醫療的融合、次世代定序(NGS) 技術的普及以及數位轉型。從人工決策轉向以人工智慧為基礎的雲端平台，標誌著精準醫療資訊學的根本性變革。儘管高成本、資料隱私和標準化等挑戰依然存在，但對技術、互通性和夥伴關係的策略性投資正為市場領導帶來持續的競爭優勢。伴隨診斷軟體正發展成為精準醫療的基礎要素，為全球醫療保健系統的基因組分析、臨床決策和患者預後改善提供支持，其長期市場前景仍然光明。

本報告的主要益處

  • 深入分析：對各個地區、客戶群、政策、社會經濟因素、消費者偏好和產業部門進行詳細的市場洞察。
  • 競爭格局：了解主要參與者的策略舉措，並確定最佳的市場進入方式。
  • 市場促進因素與未來趨勢：我們評估影響市場的關鍵成長要素和新興趨勢。
  • 實用建議：我們支援制定策略決策以開發新的收入來源。
  • 適合各類讀者：非常適合新創公司、研究機構、顧問公司、中小企業和大型企業。

公司對我們報告的使用

  • 產業和市場洞察、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、監管分析、新產品開發和競爭情報。

報告範圍

  • 歷史資料為 2021 年至 2024 年，基準年為 2025 年，預測期間為 2026 年至 2035 年。
  • 成長機會、挑戰、供應鏈前景、法律規範和趨勢分析。
  • 競爭對手定位、策略、市場佔有率評估和貿易分析。
  • 按細分市場和區域分類的銷售成長和預測評估
  • 公司簡介，包括策略、產品、財務狀況和主要發展動態。

目錄

第1章執行摘要

  • 市場概述
  • 主要發現
  • 分析師意見
  • 策略建議

第2章：調查方法

  • 調查設計
  • 資料收集和調查方法
  • 市場規模估算
  • 預測模型
  • 先決條件和限制

第3章：伴隨診斷軟體市場：概述、市場規模與預測

  • 市場定義和範圍
  • 行業概覽
  • 產業變化
  • 主要市場趨勢
  • 市場規模表現分析
  • 市場預測分析
  • 生物標記主導的精準醫療生態系分析
  • 伴隨診斷工作流程與資料管理分析
  • 貫穿整個診斷開發生命週期的軟體部署
  • 用戶採納狀況分析
  • 伴隨診斷資訊平台實施效能分析

第4章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰

第5章 行業情勢

  • 產業價值鏈分析
  • 定價分析
  • 還款狀態

第6章：創新趨勢

  • 新興技術
  • 軟體平台創新
  • 臨床試驗數據的綜合分析
  • 伴隨診斷軟體平台的流程分析
  • 技術藍圖
  • 人工智慧在伴隨診斷的應用
  • 與數位健康整合

第7章 監理情勢

  • 法律規範
  • 核准流程
  • 合規要求

第8章：伴隨診斷軟體市場：展望分析

  • 分析：按技術平台
  • 分析：依部署模式
  • 分析：透過臨床應用
  • 分析：互通性
  • 分析：按最終使用者環境

第9章：伴隨診斷軟體市場：細分市場分析

  • 軟體類型
    • 臨床決策支援軟體
    • 基因組數據分析軟體
    • 檢查資訊管理軟體
    • 配套診斷工作流程管理軟體
    • 生物資訊分析軟體
  • 按部署模式
    • 基於雲端的
    • 現場
    • 混合部署
  • 透過使用
    • 腫瘤學
    • 骨髓惡性腫瘤
    • 罕見疾病
    • 神經病變
    • 其他精準醫療應用
  • 最終用戶
    • 製藥和生物技術公司
    • 診斷檢查室
    • 受託研究機構
    • 醫院和醫療保健機構
    • 學術研究機構

第10章：伴隨診斷軟體市場：區域分析

  • 北美洲
  • 歐洲
  • 亞太地區
  • 南美洲
  • 中東和非洲

第11章：伴隨診斷軟體市場：國別分析

  • 美國
  • 加拿大
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 日本
  • 中國
  • 韓國
  • 澳洲
  • 印度

第12章 競爭格局

  • 市佔率分析
  • 策略趨勢
  • 併購、合作與聯盟
  • 新產品發布

第13章：公司簡介

  • SOPHiA GENETICS SA
  • Roche Diagnostics
  • QIAGEN NV
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Oracle Health
  • Siemens Healthineers AG
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Tempus AI, Inc.
  • PierianDx, Inc.
  • Philips Healthcare
  • Guardant Health, Inc.
  • Foundation Medicine, Inc.

第14章：伴隨診斷軟體市場：商業預測分析

第15章 投資與資金籌措分析

  • 創業投資趨勢
  • 政府資金
  • 研發投資

第16章：未來展望

  • 主要成長機遇
  • 未來產業趨勢
簡介目錄
Product Code: KSI-009069

The Companion Diagnostics Software Market is anticipated to grow at a CAGR of 15.3% from USD 1.12 billion in 2026 to USD 4.04 billion in 2035.

The companion diagnostics software market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing complexity of genomic data interpretation. The market's evolution is characterized by the increasing recognition that software platforms are essential for transforming genomic and molecular information into clinically actionable insights, enabling accurate patient stratification for targeted therapies. The convergence of next-generation sequencing, artificial intelligence, and cloud computing is enabling more efficient, scalable, and clinically relevant data interpretation. Healthcare systems and pharmaceutical companies are adopting digital precision medicine workflows because manual interpretation approaches struggle to scale alongside growing testing volumes. Regulatory oversight continues expanding because software outputs increasingly influence treatment selection and patient outcomes. The market is witnessing significant investment in AI-enabled interpretation platforms, cloud-based ecosystems, and interoperable software environments, positioning companion diagnostics software as a critical enabler of precision medicine across diagnostic testing and therapeutic decision-making.

Market Drivers

  • The expansion of precision medicine programs represents the primary driver for the companion diagnostics software market. Precision medicine requires accurate molecular interpretation to support therapy selection. Demand is increasing because pharmaceutical pipelines contain a growing number of biomarker-targeted therapies. Larger testing volumes create workflow pressure because laboratories must process genomic information rapidly without compromising accuracy. Software developers are expanding automated interpretation capabilities to improve efficiency. This trend strengthens long-term demand for companion diagnostics software solutions, resulting in sustained growth in companion diagnostics software utilization. The growth of next-generation sequencing adoption is further accelerating market expansion through increased data complexity. NGS generates comprehensive molecular datasets that support personalized treatment decisions. Utilization is increasing because clinicians require broader genomic profiling across multiple disease areas. Data complexity creates interpretation challenges because conventional analysis methods struggle to manage large-scale sequencing outputs. Software providers are developing advanced analytics and automated reporting systems to address these requirements. This evolution reinforces software importance throughout the diagnostic workflow. The increasing regulatory focus on diagnostic accuracy is driving adoption of validated software platforms. Regulatory agencies emphasize analytical validity and clinical utility for precision medicine applications. Oversight is increasing because companion diagnostics increasingly influence therapeutic outcomes. Compliance requirements create operational burdens because laboratories must document interpretation methodologies and reporting consistency. Vendors are enhancing quality management and audit functionality to support regulatory expectations. This development supports adoption of enterprise-grade software platforms. The integration of clinical and genomic data is improving precision medicine implementation across healthcare settings. Clinical decision-making depends on combining molecular findings with patient-specific information. Demand is increasing because isolated genomic data provides limited treatment context. Fragmented healthcare data environments create barriers to comprehensive analysis because information often resides in separate systems. Software providers are developing interoperable platforms that connect laboratory and clinical databases.

Market Restraints

  • High implementation and integration costs limit adoption among smaller healthcare institutions because advanced software deployment often requires substantial infrastructure investment. The significant financial commitment creates barriers for smaller facilities. Data privacy and cybersecurity requirements increase operational complexity because genomic information represents highly sensitive patient data. The sensitive nature of genomic data creates additional governance requirements. Limited availability of standardized genomic interpretation frameworks constrains scalability because variant classification approaches may differ across organizations. The lack of harmonized standards creates challenges for consistent interpretation. Integration challenges with existing laboratory and healthcare systems can create implementation delays and operational friction.

Technology and Software Type Insights

  • The software landscape is characterized by the growing importance of integrated precision medicine platforms combining interpretation, workflow management, and clinical decision support. Genomic data interpretation software represents a critical component because companion diagnostics increasingly depend on accurate molecular characterization. Demand is increasing as NGS generates larger datasets that exceed manual interpretation capabilities. Growing variant complexity creates analytical pressure because laboratories must distinguish clinically relevant findings from background genomic variation. Software developers are enhancing knowledge databases, automated annotation tools, and evidence-based reporting frameworks to improve interpretation efficiency. Clinical decision support software translates genomic findings into actionable treatment recommendations. Laboratory information management software supports workflow optimization and data management. Bioinformatics analysis software enables advanced genomic data processing. The segment analysis reveals that cloud-based deployment is expanding because healthcare organizations require flexible resources to manage expanding molecular testing volumes. Growing data storage requirements create operational challenges because genomic datasets continue increasing in size and complexity. Oncology remains the dominant application area because targeted therapies increasingly rely on biomarker-guided treatment selection. Demand is increasing as pharmaceutical developers expand precision oncology pipelines across multiple tumor types. Pharmaceutical and biotechnology companies represent the leading end-user segment, with diagnostic laboratories and healthcare providers expanding utilization. The integration of AI is becoming increasingly important because AI enhances diagnostic interpretation by identifying clinically relevant genomic patterns. Vendors are incorporating machine learning algorithms into interpretation workflows to improve efficiency.

Competitive and Strategic Outlook

  • The competitive landscape features specialized genomic analytics companies alongside established diagnostics, life science, and healthcare technology providers. SOPHiA GENETICS remains strategically distinct because it combines cloud-native analytics, artificial intelligence, and genomic interpretation capabilities within a unified precision medicine platform, expanding its SOPHiA DDM platform to improve automated variant classification and clinical decision support capabilities. Roche Diagnostics benefits from its integration of pharmaceutical development, companion diagnostics, and digital health capabilities, strengthening software-enabled genomic interpretation capabilities to support evolving precision medicine requirements. QIAGEN differentiates itself through its strong molecular diagnostics portfolio and bioinformatics infrastructure, enhancing digital interpretation platforms and knowledge databases to address growing genomic testing demands. Illumina occupies a strategic position because sequencing technology adoption continues driving demand for genomic interpretation software, expanding software-enabled analytics capabilities that support data interpretation and reporting functions. Thermo Fisher Scientific leverages its broad life sciences and molecular diagnostics portfolio to support companion diagnostic workflows, expanding digital bioinformatics capabilities that support precision medicine implementation. Agilent differentiates itself through expertise in molecular analysis, pathology workflows, and companion diagnostic support technologies, enhancing software solutions that support laboratory workflow optimization and molecular interpretation. Oracle Health benefits from extensive healthcare information technology expertise and data integration capabilities, expanding healthcare analytics and cloud infrastructure capabilities that support integration of genomic and clinical data. Siemens Healthineers maintains a competitive position through its combination of diagnostic technologies, healthcare informatics, and digital health solutions, expanding digital health capabilities that support advanced diagnostics and decision-making processes. Companies are pursuing product portfolio expansion through innovation in AI-enabled interpretation, cloud-based platforms, and interoperable software environments. Strategic collaborations between software providers and pharmaceutical companies are increasing, driven by the need for integrated biomarker development support. Recent key developments include Indica Labs announcing a major expansion of its companion diagnostics capabilities, positioning the company at the forefront of precision medicine innovation. Labcorp announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the FDA to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

  • The companion diagnostics software market is positioned for sustained growth driven by the convergence of precision medicine, NGS adoption, and digital transformation. The transition from manual interpretation toward AI-enabled, cloud-based platforms represents a fundamental shift in precision medicine informatics. While challenges related to high costs, data privacy, and standardization persist, strategic investments in technology, interoperability, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with companion diagnostics software evolving into a foundational component of precision medicine, supporting genomic interpretation, clinical decision-making, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

  • 1.1 Market Snapshot
  • 1.2 Key Findings
  • 1.3 Analyst Insights
  • 1.4 Strategic Recommendations

2. Research Methodology

  • 2.1 Research Design
  • 2.2 Data Collection Methodology
  • 2.3 Market Size Estimation
  • 2.4 Forecasting Model
  • 2.5 Assumptions & Limitations

3. Companion Diagnostics Software Market Overview, Size & Forecast

  • 3.1 Market Definition & Scope
  • 3.2 Industry Overview
  • 3.3 Industry Evolution
  • 3.4 Key Market Trends
  • 3.5 Historical Market Size Analysis (2021-2025)
  • 3.6 Market Forecast Analysis (2026-2035)
  • 3.7 Biomarker-Driven Precision Medicine Ecosystem Analysis
  • 3.8 Companion Diagnostics Workflow and Data Management Analysis
  • 3.9 Software Adoption Across Diagnostic Development Lifecycle
  • 3.10 User Adoption Analysis
  • 3.11 Installed Base Analysis of Companion Diagnostics Informatics Platforms

4. Market Dynamics

  • 4.1 Market Drivers
  • 4.2 Market Restraints
  • 4.3 Market Opportunities
  • 4.4 Market Challenges

5. Industry Landscape

  • 5.1 Industry Value Chain Analysis
  • 5.2 Pricing Analysis
  • 5.3 Reimbursement Landscape

6. Innovation Landscape

  • 6.1 Emerging Technologies
  • 6.2 Software Platform Innovation
  • 6.3 Clinical Trial Data Integration Analysis
  • 6.4 Pipeline Analysis of Companion Diagnostics Software Platforms
  • 6.5 Technology Roadmap
  • 6.6 AI Integration in Companion Diagnostics
  • 6.7 Digital Health Integration

7. Regulatory Landscape

  • 7.1 Regulatory Framework
  • 7.2 Approval Pathways
  • 7.3 Compliance Requirements

8. Companion Diagnostics Software Market Landscape Analysis

  • 8.1 Analysis by Technology Platform
  • 8.2 Analysis by Deployment Model
  • 8.3 Analysis by Clinical Application
  • 8.4 Analysis by Interoperability Capabilities
  • 8.5 Analysis by End-user Environment

9. Companion Diagnostics Software Market Segment Analysis (2021-2035)

  • 9.1 By Software Type
    • 9.1.1 Clinical Decision Support Software
    • 9.1.2 Genomic Data Interpretation Software
    • 9.1.3 Laboratory Information Management Software
    • 9.1.4 Companion Diagnostics Workflow Management Software
    • 9.1.5 Bioinformatics Analysis Software
  • 9.2 By Deployment Model
    • 9.2.1 Cloud-Based
    • 9.2.2 On-Premises
    • 9.2.3 Hybrid Deployment
  • 9.3 By Application
    • 9.3.1 Oncology
    • 9.3.2 Hematologic Malignancies
    • 9.3.3 Rare Diseases
    • 9.3.4 Neurological Disorders
    • 9.3.5 Other Precision Medicine Applications
  • 9.4 By End User
    • 9.4.1 Pharmaceutical & Biotechnology Companies
    • 9.4.2 Diagnostic Laboratories
    • 9.4.3 Contract Research Organizations
    • 9.4.4 Hospitals & Healthcare Providers
    • 9.4.5 Academic & Research Institutes

10. Companion Diagnostics Software Market Geographical Analysis (2021-2035)

  • 10.1 North America
  • 10.2 Europe
  • 10.3 Asia-Pacific
  • 10.4 South America
  • 10.5 Middle East & Africa

11. Companion Diagnostics Software Market Country Analysis (2021-2035)

  • 11.1 United States
  • 11.2 Canada
  • 11.3 Germany
  • 11.4 United Kingdom
  • 11.5 France
  • 11.6 Italy
  • 11.7 Spain
  • 11.8 Japan
  • 11.9 China
  • 11.10 South Korea
  • 11.11 Australia
  • 11.12 India

12. Competitive Landscape

  • 12.1 Market Share Analysis
  • 12.2 Strategic Developments
  • 12.3 Mergers & Acquisitions, Partnerships & Collaborations
  • 12.4 Product Launches

13. Company Profiles

  • 13.1 SOPHiA GENETICS SA
  • 13.2 Roche Diagnostics
  • 13.3 QIAGEN N.V.
  • 13.4 Illumina, Inc.
  • 13.5 Thermo Fisher Scientific Inc.
  • 13.6 Agilent Technologies, Inc.
  • 13.7 Oracle Health
  • 13.8 Siemens Healthineers AG
  • 13.9 Danaher Corporation
  • 13.10 Bio-Rad Laboratories, Inc.
  • 13.11 Tempus AI, Inc.
  • 13.12 PierianDx, Inc.
  • 13.13 Philips Healthcare
  • 13.14 Guardant Health, Inc.
  • 13.15 Foundation Medicine, Inc.

14. Companion Diagnostics Software Market Commercial Forecast Analysis

  • 14.1 Clinical Decision Support Software Forecast
  • 14.2 Genomic Interpretation Software Forecast
  • 14.3 Laboratory Information Management Software Forecast
  • 14.4 Bioinformatics Analysis Software Forecast
  • 14.5 Workflow Management Software Forecast

15. Investment & Funding Analysis

  • 15.1 Venture Capital Trends
  • 15.2 Government Funding
  • 15.3 R&D Investments

16. Future Outlook

  • 16.1 Key Growth Opportunities
  • 16.2 Future Industry Trends